Studies are increasingly showing that what many once dismissed as “benign” fat in the liver may carry far more weight—literally and figuratively. According to a recent article by the American Cancer Society (ACS), the conditions known as Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its more advanced form, Metabolic dysfunction‐associated steatohepatitis (MASH), are rapidly emerging as significant risk factors not only for liver disease but for cancer.
More than one-third of U.S. adults are estimated to have MASLD, with the prevalence expected to rise sharply over the next three decades. While other causes of liver cancer are declining, MASLD and MASH are now recognized as major contributors — with roughly 11,000 new liver cancer cases each year attributed to these conditions.
What Are MASLD and MASH?
MASLD, formerly known by the term non-alcoholic fatty liver disease (NAFLD), is characterized by fat accumulation in the liver unrelated to heavy alcohol consumption. When the disease advances to include inflammation and liver cell injury, it evolves into MASH (formerly NASH: non-alcoholic steatohepatitis).
The fat buildup triggers inflammation, which may lead to fibrosis (scar tissue) and eventually cirrhosis. That process sets the stage for higher cancer risk.
Who’s at Risk and Why It Matters
Risk factors for MASLD/MASH include:
- Excess body weight (particularly obesity)
- Type 2 diabetes
- High blood pressure and high cholesterol
- A family history of fatty liver disease
- Even for those who are not heavy drinkers, alcohol can worsen MASLD/MASH when combined with metabolic risks.
Why does this matter? Because having MASLD or MASH can lead to serious outcomes, including:
- Cirrhosis (severe scarring of the liver)
- Liver failure
- Liver cancer (especially hepatocellular carcinoma)
- Other gastrointestinal cancers, such as esophageal, stomach, and colorectal cancer
- Cardiovascular disease, including heart attack and stroke
The key takeaway: even though many people with MASLD are asymptomatic, the long-term implications can be serious. Early recognition and intervention are crucial.
Signs, Symptoms, and When to Talk to a Doctor
Since MASLD often has no symptoms initially, it may be uncovered during routine lab work or imaging. Some possible signs can include:
- Persistent fatigue despite adequate sleep
- A heavy or uncomfortable feeling on the right side of the abdomen
- Yellowing of the skin or eyes (jaundice)
- Swelling in the belly or lower extremities
- Increased bruising
If you have one or more of the known risk factors (e.g., obesity, type 2 diabetes, metabolic syndrome), it’s important to engage your physician in the conversation. A typical screening approach may include checking liver-enzyme levels (transaminases) and, if those are elevated, referral to a gastroenterologist or hepatologist for further evaluation including imaging like an ultrasound.
Strategies to Lower Risk & Support Liver Health
Fortunately, there are actionable steps that can make a meaningful difference:
- Weight loss: Even a reduction of 7 %–10 % of body weight may reduce liver fat, decrease inflammation, and potentially reverse scarring.
- Healthy diet and physical activity: These foundational habits protect liver-health and reduce cancer risk.
- Limit or avoid alcohol consumption: Especially important for those with fatty liver disease or a metabolic risk profile.
- Manage metabolic conditions: Effective treatment of diabetes, high cholesterol, and hypertension can all support liver function and reduce progression.
- Regular health checkups: Early recognition of elevated liver enzymes or imaging findings may prompt timely intervention.
It’s important to note: while these approaches can reduce risk and slow progression, they cannot guarantee prevention of all cases of MASLD/MASH or liver cancer. The earlier the condition is identified and managed, the better the outcomes tend to be.
Why This Matters for Healthcare Providers & Screening Services
For clinical service providers—including those focused on imaging, diagnostics, and early detection—the growing prominence of MASLD/MASH underscores an opportunity: ensuring patients with metabolic risk factors are appropriately screened and monitored for liver involvement. Non-invasive imaging modalities (such as ultrasound and elastography) are increasingly important tools for early detection and staging of liver disease.
From a public-health perspective, the shift in liver-disease etiology from primarily alcohol-related to predominantly metabolic dysfunction-related demands updated protocols and awareness efforts in preventive care. It also positions liver imaging and non-invasive fibrosis assessment as strategic elements in broader cancer-risk management frameworks.
Bottom Line
The evolving narrative around liver disease emphasizes that fatty liver is not always harmless. With millions affected and projections rising, MASLD and its inflammatory progression MASH are now key players in liver-cancer risk. Recognizing the risk, engaging in lifestyle changes, and working closely with healthcare providers to monitor liver health represent the best available approach today.
Source: American Cancer Society. (October 9, 2025). MASLD and MASH: Fatty Liver Disease and Cancer Risk. Retrieved from https://www.cancer.org/cancer/latest-news/masld-and-mash-fatty-liver-disease-and-cancer-risk.html
Note: This article is for general informational purposes only and does not constitute medical advice. Individuals should consult with their healthcare provider for personalized assessment and recommendations.
